Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents-Reference-Cited by-同舟云学术

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

Published:2013-02 Issue:2 Volume:88 Page:139-148
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Bowlin Steven J.,Xia Fang,Wang Wenyi,Robinson Keisha D.,Stanek Eric J.

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. SEER Cancer Statistics Review, 1975-2008;Howlader,2011

2. Potential for drug interactions in hospitalized cancer patients;Riechelmann;Cancer Chemother Pharmacol,2005

3. Potential drug interactions and duplicate prescriptions among cancer patients;Riechelmann;J Natl Cancer Inst,2007

4. Potential drug interactions in cancer patients receiving supportive care exclusively;Riechelmann;J Pain Symptom Manage,2008

5. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? a prospective pilot study;Puts;Drugs Aging,2009

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions;CPT: Pharmacometrics & Systems Pharmacology;2024-03-14

2. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

3. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape;Expert Review of Clinical Pharmacology;2023-02-01

4. The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia;International Journal of Hematologic Oncology;2022-03

5. Flavonoid-Mediated Modulation of CYP3A Enzyme and P-Glycoprotein Transporter: Potential Effects on Bioavailability and Disposition of Tyrosine Kinase Inhibitors;Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health;2021-04-07